Post-stroke treatments exist but are limited, so scientists are actively searching for new options. What have they discovered? DMT, or dimethyltryptamine, may offer a promising solution.
A study published in Science Advances found that DMT can reduce the harmful effects of stroke in both animal models and cell culture experiments.
Exciting, isn’t it? This could represent a step forward for stroke patients.
Table of Contents
- Limitations of Post-Stroke Rehabilitation or Treatment
- Study From the HUN-REN BRC Institute of Biophysics and Semmelweis University Heart and Vascular Centre
- An Adjunct Solution to Existing Stroke Treatment
- Is There a Human Trial Already?
- Trying Dimethyltryptamine for Stroke Patients
- Dimethyltryptamine, a New Hope for Stroke Patients, Get It at Zoomies Canada
- Frequently Asked Questions
Limitations of Post-Stroke Rehabilitation or Treatment
While post-stroke rehabilitation can help patients regain lost functions, it comes with limitations. Recovery is influenced by factors such as the severity of brain damage, timing of treatment, accessibility of therapy, and health conditions.
- Current therapies can help recovery, but full restoration is impossible, especially if large areas of the brain are damaged.
- Many patients don’t access therapy quickly enough, so it’s limiting the effectiveness of rehabilitation.
- One-size-fits-all approaches are insufficient; personalized rehab plans are needed, but may not always be feasible.
- Medications mainly focus on preventing secondary strokes or managing symptoms, not repairing brain tissue.
The limitation of treatments is why scientists need to explore more options.
| Dimethyltryptamine is available online through Zoomies Canada. We deliver directly to your doorstep. | Buy Psychedelics |
Study From the HUN-REN BRC Institute of Biophysics and Semmelweis University Heart and Vascular Centre
Published in August 2025, a study by Prof. Mária Deli, Prof. Zoltán Nagy, Dr. Sándor Nardai, and colleagues found that DMT reduced infarct size and swelling in a rat model of stroke. In both animal and cell culture experiments, dimethyltryptamine helped restore the structure and function of the damaged blood-brain barrier (BBB) and improved the performance of astroglial cells.
The compound also modulated peripheral immune responses, decreasing proinflammatory cytokines while increasing anti-inflammatory IL-10 and neurotrophic BDNF, all of which are associated with better stroke recovery.
DMT’s effects were largely mediated through sigma-1 receptors. It acts on both central neurovascular cells and peripheral immune cells. It protected BBB integrity, reduced microglial activation, and supported overall neurovascular health. These findings highlight a complementary approach to current post-stroke therapies.
An Adjunct Solution to Existing Stroke Treatment
Dimethyltryptamine has the potential to serve as a therapeutic adjuvant to existing stroke treatments. Current options for stroke remain very limited, and full recovery is elusive. The dual action of dimethyltryptamine, protecting the blood-brain barrier while simultaneously reducing neuroinflammation, offers a sophisticated, multifaceted approach that could complement conventional therapies.
Recent research from Szeged and Budapest supports the development of such therapies. These studies suggest a path that goes beyond the constraints of traditional stroke treatment. While clinical trials have already begun internationally and investigations into the long-term effects are underway, research remains before it can be incorporated into routine medical practice.
Is There a Human Trial Already?
All drug treatments begin with animal studies before progressing to human clinical trials. Yes, there is an ongoing trial using dimethyltryptamine for stroke patients.
Algernon Pharmaceuticals Inc. has submitted a pre-Investigational New Drug (IND) meeting request to the FDA to discuss its research on AP-188 (N, N-dimethyltryptamine) as a potential treatment for stroke-related impairment.
In this request, Algernon is seeking guidance on using dimethyltryptamine alongside constraint-induced movement therapy (CIMT) to treat upper-limb dysfunction in stroke patients.
Algernon’s decision to advance DMT into human clinical trials for stroke is supported by extensive preclinical evidence showing that the compound promotes neurogenesis and enhances both structural and functional neural plasticity.
Current Status
Algernon Pharmaceuticals Inc. has completed Phase 1 of the study in the first quarter of 2024 and is now preparing to begin the second phase, scheduled to start in the third quarter of this year.
The upcoming Phase 2a trial will be a randomized, double-blind, placebo-controlled study involving 40 ischemic stroke patients, with safety as the primary focus.
Secondary measures will evaluate whether sub-psychedelic doses of DMT can improve cognitive functions, as well as reduce the size of the damaged brain area (infarct volume). A separate Phase 2a study for traumatic brain injury (TBI) is also being planned.
Trying Dimethyltryptamine for Stroke Patients
You can, but you must consult your doctor first to determine whether any of your medications could interact with dimethyltryptamine.
When using dimethyltryptamine, safety should always come first. This includes:
- Being mentally prepared
- Using safe, tested products
- Taking the correct dosage
- Having a trip sitter
- Staying in a quiet, calming environment
Dimethyltryptamine, a New Hope for Stroke Patients, Get It at Zoomies Canada
About 878,500 Canadian adults aged 20 and older have experienced a stroke. While treatments are available, they can be costly or take time to access. This is why research into new therapeutic options is so important, especially when early studies show promising results. Dimethyltryptamine may serve as a strong adjunct therapy, and safe access is available through Zoomies Canada, a shroom dispensary.
Frequently Asked Questions
What dosage of dimethyltryptamine is suitable for treating stroke?
Since dimethyltryptamine is not yet formally approved as a treatment, there is no standardized dosage. However, in some studies, even the highest doses used remained below the psychedelic threshold. This means they did not produce the intense hallucinogenic effects associated with the substance.
Can ayahuasca be used as an alternative to DMT for therapeutic purposes?
Ayahuasca contains dimethyltryptamine along with other plant compounds, but it is not a direct substitute for dimethyltryptamine used in research or treatment. The combination of ingredients in ayahuasca produces strong psychedelic effects and can vary in potency.
Which type of stroke has shown a response to dimethyltryptamine in studies?
Studies on dimethyltryptamine have focused on ischemic stroke. Researchers use animal models that closely mimic human ischemic stroke to test DMT’s effects. They measure infarct size (area of brain damage) and edema (swelling) to assess how well the substance protects the brain and aids recovery.
